Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 18/20 | 0.56 |
| ▸ | ITGA4 | P13612 | 18/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | NPR3 | P17342 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7258634 | 0.93 | ITGB1 (0.49) | ITGB1ITGA4ADORA3 | |
| SCHEMBL7589143 | 0.92 | ITGB1 (0.47) | ITGB1ITGA4ADORA3NPR3 | |
| SCHEMBL7710752 | 0.91 | ITGB1 (0.54) | ITGB1ITGA4NPR3 | |
| SCHEMBL7714166 | 0.91 | ITGB1 (0.57) | ITGB1ITGA4 | |
| SCHEMBL7714171 | 0.91 | ITGB1 (0.54) | ITGB1ITGA4NPR3 | |
| SCHEMBL7716467 | 0.90 | ITGB1 (0.53) | ITGB1ITGA4NPR3 | |
| SCHEMBL7104336 | 0.87 | ITGB1 (0.60) | ITGB1ITGA4NPR3 | |
| SCHEMBL7716204 | 0.85 | ITGB1 (0.49) | ITGB1ITGA4 | |
| SCHEMBL7714179 | 0.84 | ITGB1 (0.49) | ITGB1ITGA4NPR3 | |
| SCHEMBL7258056 | 0.84 | ITGB1 (0.43) | ITGB1ITGA4ADORA3NPR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1305291-A1 | 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES | Celltech R&D Limited (GB) | 2003-05-02 | — | — | EP | claimed |
| US-20020177605-A1 | 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES | CELLTECH R&D, LTD. (GB) | 2002-11-28 | — | — | US | claimed |
| US-6469025-B1 | FOR THE PROPHYLAXIS OR TREATMENT OF A DISEASE OR DISORDER IN A MAMMAL IN WHICH THE EXTRAVASATION OF LEUKOCYTES PLAYS A ROLE; INHIBITING THE BINDING OF ALPHA 4 INTEGRINS TO THEIR LIGANDS | CELLTECH R&D LTD. (GB) | 2002-10-22 | — | — | US | claimed |
| WO-2002010136-A1 | 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2002-02-07 | — | — | WO | claimed |
| EP-1305291-A1 | 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES | Celltech R&D Limited (GB) | 2003-05-02 | — | — | EP | disclosed |
| US-20020177605-A1 | 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES | CELLTECH R&D, LTD. (GB) | 2002-11-28 | — | — | US | disclosed |
| WO-2002010136-A1 | 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177605-A1 | 3-SUBSTITUTED ISOQUINOLIN-1-YL DERIVATIVES | ICAM1, VCAM1, CCR1 | ITGB1 8/4885ITGA4 98/4885ADORA3 1867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.